Biocryst医药

#药闻简讯# $Biocryst医药(BCRX)$
Orladeyo 第四季度销售额达 1.51 亿美元
2026年预期收入为6.25亿至6.45亿美元
3.38亿美元现金

$Biocryst医药(BCRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000882796-25-000021  Size: 4 KB 网页链接

$Biocryst医药(BCRX)$ 144 Report of proposed sale of securities Accession Number: 0001959173-25-007427  Act: 33  Size: 10 KB 网页链接

$Biocryst医药(BCRX)$ 425 Prospectuses and communications, business combinations Accession Number: 0001140361-25-044111  Size: 528 KB 网页链接

$Biocryst医药(BCRX)$ 8-K Current report, item 5.02 Accession Number: 0001171843-25-007878  Act: 34  Size: 186 KB 网页链接

$Biocryst医药(BCRX)$ 144 Report of proposed sale of securities Accession Number: 0001959173-25-007471  Act: 33  Size: 9 KB 网页链接

$Biocryst医药(BCRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000882796-25-000033  Size: 6 KB 网页链接

$Biocryst医药(BCRX)$ 8-K Current report, item 7.01 Accession Number: 0001171843-26-000154  Act: 34  Size: 185 KB 网页链接

$Biocryst医药(BCRX)$ 144 Report of proposed sale of securities Accession Number: 0001959173-25-006976  Act: 33  Size: 5 KB 网页链接

$Biocryst医药(BCRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000882796-25-000017  Size: 4 KB 网页链接

$Biocryst医药(BCRX)$ RA Capital Management, L.P. 联合彼得·科尔钦斯基（Peter Kolchinsky）和拉吉夫·沙阿（Rajeev Shah）提交了Schedule 13G文件，报告持有BioCryst Pharmaceuticals, Inc. 7.3%的股权。申报显示RA Capital Healthcare Fund, L.P.直接持有15,302,186股BioCryst普通股。RA Capi...

$Biocryst医药(BCRX)$ SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors Accession Number: 0001346824-25-000052  Act: 34  Size: 18 KB 网页链接

$Biocryst医药(BCRX)$ S-4 Registration of securities, business combinations Accession Number: 0001140361-25-042879  Act: 33  Size: 4 MB 网页链接

$Biocryst医药(BCRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000882796-25-000019  Size: 4 KB 网页链接

$Biocryst医药(BCRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000882796-25-000023  Size: 4 KB 网页链接

$Biocryst医药(BCRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001171843-25-008039  Size: 16 KB 网页链接

$Biocryst医药(BCRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000882796-25-000031  Size: 6 KB 网页链接

$Biocryst医药(BCRX)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001171843-26-000446  Size: 11 KB 网页链接

$Biocryst医药(BCRX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001140361-25-044110  Act: 34  Size: 668 KB 网页链接

$Biocryst医药(BCRX)$ 144 Report of proposed sale of securities Accession Number: 0001959173-25-007729  Act: 33  Size: 6 KB 网页链接